The China's State Food and Drug Administration (SFDA) has granted approval to Sensus Healthcare for its superficial radiotherapy system, SRT-100.
The SRT-100 system is designed for delivering radiotherapy waves superficially for the treatment of non-melanoma skin cancer.
Based on the approval, the company’s distribution partner, Megatop MTC, has ordered 9 systems for selling them in China.
Megatop MTC managing director George Shum said, "Our success in Hong Kong over the past 2 years has already put us in good position to draw the attention of leading hospitals in China."
Sensus Healthcare president and CEO Joe Sardano said there are many applications for SRT treatment in the Chinese healthcare market.
"We are excited to be working with our distribution partner, Megatop MTC, as we begin our sales and marketing initiatives and we thank and congratulate the authorities in China for allowing us the opportunity to serve their healthcare community," Sardano added.